Brean Capital upgraded shares of NPS Pharmaceuticals (NASDAQ:NPSP) from a hold rating to a buy rating in a report released on Wednesday, TheFlyOnTheWall.com reports. Brean Capital currently has $36.00 price objective on the stock.
NPS Pharmaceuticals (NASDAQ:NPSP) traded up 3.59% on Wednesday, hitting $24.51. 1,502,414 shares of the company’s stock traded hands. NPS Pharmaceuticals has a one year low of $7.35 and a one year high of $35.72. The stock’s 50-day moving average is $30.22 and its 200-day moving average is $21.40. The company’s market cap is $2.486 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.02) by $0.01. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $38.40 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $-0.21 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at MLV Capital raised their price target on shares of NPS Pharmaceuticals from $18.00 to $39.00 in a research note to investors on Thursday, October 17th. They now have a buy rating on the stock. Separately, analysts at Summer Street raised their price target on shares of NPS Pharmaceuticals from $33.00 to $39.00 in a research note to investors on Wednesday, October 9th. They now have a buy rating on the stock. Finally, analysts at Merrill Lynch initiated coverage on shares of NPS Pharmaceuticals in a research note to investors on Thursday, October 3rd. They set a buy rating and a $46.00 price target on the stock. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $36.89.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.